Caplin Point Laboratories Limited — Updates, 23-04-2025: Press Release

Caplin Steriles Limited has secured final approval from the USFDA for its Phytonadione Injectable Emulsion, a generic equivalent to VITAMIN K1 Injection from Hospira Inc. This product is crucial for treating coagulation disorders linked to vitamin K deficiency, which can impair the formation of specific blood factors. US sales for this injectable emulsion reached approximately $18.5 million over the last year, indicating significant market potential.

Caplin Steriles is rapidly expanding its portfolio, having filed 47 ANDAs in the US, with 35 approvals to date. The company aims to develop more than 40 additional injectable and ophthalmic products over the next four years. This approval enhances Caplin Point Laboratories' position in the pharmaceutical sector, particularly in emerging markets where it already shows robust growth in revenues and profitability. Investors should view this as a positive development, given the potential for revenue generation in the growing injectable market.